AlphAIalphai — Financial news for AI agents
MarketBeatMAR 174 min read$DCGO

DocGo (NASDAQ:DCGO) Price Target Cut to $2.50 by Analysts at Stifel Nicolaus

Stifel Nicolaus has lowered its price target for DocGo (NASDAQ:DCGO) to $2.50 from $4.00, while maintaining a "buy" rating, indicating a potential upside of 218%. Despite a Q4 revenue beat and raised 2026 revenue guidance of $290M–$310M, the company faces significant execution risk due to a large EPS miss, year-over-year revenue decline, and weak margins, with the stock currently trading around $0.79. DocGo is exploring strategic alternatives to push towards profitability.

Original reporting
MarketBeat · MarketBeat
Published Mar 17, 2026, 2:46 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 17, 2026, 3:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
DocGo (NASDAQ:DCGO) Price Target Cut to $2.50 by Analysts at Stifel Nicolaus — source image
Source · MarketBeat
Decision brief

The 30-second read

$DCGOBearishLow
01

Why it matters

However, the analyst's significant price target cut and concerns over EPS and margins suggest underlying challenges that could impact stock performance.

02

Market read

The news is highly relevant to current and potential investors in DocGo, especially those trading on short to medium-term horizons.

03

What to watch

Potential for a short squeeze if the stock remains undervalued and trading volume increases; upcoming catalysts such as strategic alternatives announcement could alter the outlook.

Timing: short-term

Background

DocGo reported a Q4 revenue beat and raised revenue guidance for 2026, indicating operational strength.

Company-level read

Ticker impact

$DCGOBearishMedium confidence
Context

The news directly pertains to DocGo (NASDAQ:DCGO), highlighting a significant analyst price target revision and company performance factors.

Expected impact

Potential short-term decline or sideways movement; long-term outlook remains uncertain due to execution risks.

Evidence & confidence

The conflicting signals—positive revenue guidance versus negative analyst outlook and execution risks—create uncertainty. Technical levels and current valuation suggest limited upside, but the low stock price leaves room for volatility.

Market effects

Sector

The healthcare and life sciences sectors may experience slight negative sentiment due to company-specific issues.

Regional

Limited regional impact; the news is specific to a US-listed company.

Global

Minimal; the company's size and market cap suggest limited influence on global markets.

Counterpoint

What could challenge this read

The lowered price target may already be priced in, and the company's strategic initiatives could lead to future upside if execution improves.

Key entities

  • Financial Analyst Firm
    Stifel Nicolaus

    The firm that revised the price target for DocGo.

  • Company
    DocGo

    The subject of the analyst review, operating in healthcare services.

Read at source← All news

Related articles

AUG 18
$DCGOHighAI 9/10

Why is DocGo stock tumbling today?

DocGo (DCGO) shares fell 12.7% pre-open to $0.62 after its Q2 2026 adjusted loss was $0.16 per share versus $0.10 consensus. Revenue was $73.4M, below $75.4M forecast and down 8.7% YoY, tied to wind-down of migrant contracts. It widened FY2026 adjusted EBITDA loss to $17M-$22M and agreed to acquire Hicuity Health (~$65M trailing revenue).

investing.com4 min
AUG 18
$DCGOHighAI 9/10

Why is DocGo stock sliding today?

DocGo (DCGO) shares fell about 12.7% pre-open to $0.62 after its Q2 2026 results missed expectations. Adjusted loss per share was $0.16 vs $0.10 forecast, revenue was $73.4M vs $75.4M. DocGo cut full-year 2026 adjusted EBITDA guidance to a $17M to $22M loss and agreed to acquire Hicuity Health, largely via debt assumption and new financing.

investing.com4 min
AUG 17
$DCGOMed

Why is DocGo stock gaining in after-hours trading today?

DocGo (DCGO) shares rose 2.4% in after-hours to $0.727 after its Q2 2026 earnings release and a 5:00 p.m. ET management call. Analysts expected a 15-cent per-share loss versus a 21-cent loss a year earlier. DocGo also sought a short SEC 10-Q filing extension and reiterated no major operating changes, with prior FY2026 sales guidance raised and a $26M buyback extended.

investing.com5 min
AUG 17
$DCGOMed

DocGo Inc. (DCGO): Results of Operations and Financial Condition

DocGo Inc. (DCGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-2.1 2 exhibit2mergeragreement.htm EX-2.1 Document EXECUTION VERSION AGREEMENT AND PLAN OF MERGER dated as of August 16, 2026 among DocGo Inc., Ambulnz Holdings, LLC, HH Merger Sub, LLC, Hicuity Health, Inc., Concord Innovation Fund II, LP, and Concord Innovation Fund II, LP, a

SEC EDGAR 8-K6 min
AUG 19
$COSTMed

Costco Is Launching Medicare Plans — Here’s What Seniors Need to Know Before Open Enrollment

Costco (COST) is partnering with SCAN Health Plan to launch co-branded Medicare Advantage plans in three states, pending federal approval. The plans will be sold in Costco warehouses, online, and through agents, with no membership requirement. The move aims to integrate health services with Costco's existing offerings. Details on premiums and benefits are not yet available.

savingadvice.com4 min